Healthcare Resource Utilization in a Phase 3 Study of CPX-351 in Patients With Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia

Journal of Medical Economics - United Kingdom
doi 10.1080/13696998.2020.1744613
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Informa UK Limited

Related search

The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients With Newly Diagnosed, High-Risk/Secondary AML (sAML)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2014English

Nilotinib vs Imatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase: ENESTnd 3-Year Follow-Up

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Enasidenib, an Inhibitor of Mutant IDH2 Proteins, Induces Durable Remissions in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Phase 1 Study of the MDM2 Antagonist RO6839921 in Patients With Acute Myeloid Leukemia

Investigational New Drugs
OncologyPharmacology
2020English

Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 With Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2018English

Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy